» Articles » PMID: 38063990

Comparative Study of Indocyanine Green Fluorescence Imaging in Lung Cancer with Near-Infrared-I/II Windows

Overview
Journal Ann Surg Oncol
Publisher Springer
Specialty Oncology
Date 2023 Dec 8
PMID 38063990
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We compare the application of intravenous indocyanine green (ICG) fluorescence imaging in lung cancer with near-infrared-I (NIR-I) and near-infrared-II (NIR-II) windows.

Methods: From March to December 2022, we enrolled patients who received an intravenous injection of ICG (5 mg/kg) 1 day before the planned lung cancer surgery. The lung cancer nodules were imaged by NIR-I/II fluorescence imaging systems, and the tumor-to-normal-tissue ratio (TNR) was calculated. In addition, the fluorescence intensity and signal-to-background ratio (SBR) of capillary glass tubes containing ICG covered with different thicknesses of lung tissue were measured by NIR-I/II fluorescence imaging systems.

Results: In this study, 102 patients were enrolled, and the mean age was 59.9 ± 9.2 years. A total of 96 (94.1%) and 98 (96.1%) lung nodules were successfully imaged with NIR-I and NIR-II fluorescence, and the TNR of NIR-II was significantly higher than that of NIR-I (3.9 ± 1.3 versus 2.4 ± 0.6, P < 0.001). In multiple linear regression, solid nodules (P < 0.001) and squamous cell carcinoma (P < 0.001) were independent predictors of a higher TNR of NIR-I/II. When capillary glass tubes were covered with lung tissue whose thickness was more than 2 mm, the fluorescence intensity and the SBR of NIR-II were significantly higher than those of NIR-I.

Conclusions: We verified the feasibility of NIR-II fluorescence imaging in intravenous ICG lung cancer imaging for the first time. NIR-II fluorescence can improve the TNR and penetration depth of lung cancer with promising clinical prospects.

Citing Articles

Recent Advances in Indocyanine Green-Based Probes for Second Near-Infrared Fluorescence Imaging and Therapy.

Hu D, Zha M, Zheng H, Gao D, Sheng Z Research (Wash D C). 2025; 8():0583.

PMID: 39830366 PMC: 11739436. DOI: 10.34133/research.0583.


Progression in Near-Infrared Fluorescence Imaging Technology for Lung Cancer Management.

Chen X, Li Y, Su J, Zhang L, Liu H Biosensors (Basel). 2024; 14(10).

PMID: 39451714 PMC: 11506746. DOI: 10.3390/bios14100501.


NIR-II light in clinical oncology: opportunities and challenges.

Zhang Z, Du Y, Shi X, Wang K, Qu Q, Liang Q Nat Rev Clin Oncol. 2024; 21(6):449-467.

PMID: 38693335 DOI: 10.1038/s41571-024-00892-0.

References
1.
Gould M, Tang T, Liu I, Lee J, Zheng C, Danforth K . Recent Trends in the Identification of Incidental Pulmonary Nodules. Am J Respir Crit Care Med. 2015; 192(10):1208-14. DOI: 10.1164/rccm.201505-0990OC. View

2.
Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K . Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022; 399(10335):1607-1617. DOI: 10.1016/S0140-6736(21)02333-3. View

3.
Taioli E, Yip R, Olkin I, Wolf A, Nicastri D, Henschke C . Survival after Sublobar Resection for Early-Stage Lung Cancer: Methodological Obstacles in Comparing the Efficacy to Lobectomy. J Thorac Oncol. 2016; 11(3):400-6. DOI: 10.1016/j.jtho.2015.10.022. View

4.
Aliperti L, Predina J, Vachani A, Singhal S . Local and systemic recurrence is the Achilles heel of cancer surgery. Ann Surg Oncol. 2010; 18(3):603-7. PMC: 11156256. DOI: 10.1245/s10434-010-1442-0. View

5.
Sato M . Precise sublobar lung resection for small pulmonary nodules: localization and beyond. Gen Thorac Cardiovasc Surg. 2019; 68(7):684-691. DOI: 10.1007/s11748-019-01232-1. View